¼¼°èÀÇ µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : À¯Çüº°, ¿¬·ÉÃþº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº°-»ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¿¹Ãø(2024-2032³â)
Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market, By Type, By Age Group, By End User, By Country, and By Region - Industry Analysis, Market End User, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1629186
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,520,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,467,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,858,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ÃÖÁ¾ »ç¿ëÀÚ ½ÃÀåÀº 2023³â 56¾ï 2,032¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8.30%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå ¿ªÇÐ

À¯¾Æ ¹× ¼Ò¾ÆÀÇ DPT °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤ºÎ ÇÁ·Î±×·¥¿¡ ÀÇÇÑ °è¹ßÀÇ °íÁ¶°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ Àü¸Á

¹é½ÅÁ¢Á¾ÀÇ Á߿伺À» ±¹¹Î¿¡°Ô °è¸ùÇϱâ À§ÇÑ Á¤ºÎ³ª Á¶Á÷¿¡ ÀÇÇÑ ´ëó Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. WHOÀÇ ¿¹¹æÁ¢Á¾ È®´ë ÇÁ·Î±×·¥(EPI)°ú ¹é½Å µ¿¸Í GAVI¿Í °°Àº ÇÁ·Î±×·¥Àº DPT °ü·Ã Áúȯ¿¡ ´ëÇÑ ¿¹¹æÁ¢Á¾ º¸±ÞÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼Ò¾Æ¿¡¼­ÀÇ µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódzÀÇ À§Çè¿¡ ´ëÇÑ ÀÌÇØÀÇ Çâ»óÀÌ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¹°¡ÀÇ ¿¹¹æ Á¢Á¾ ÀÏÁ¤¿¡ DPT ¹é½ÅÀÌ Æ÷ÇԵǾî ÀÖÀ½¿¡µµ ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº Á¤ºÎ°¡ ¹é½ÅÀ» °ÅÀÇ ¶Ç´Â ¹«·á·Î Á¦°øÇϱ⠶§¹®¿¡ ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¾ÊÀº »ç¶÷µéµµ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯¾Æ´Â ƯÈ÷ DPT °ü·Ã Áúȯ¿¡ °É¸®±â ½±½À´Ï´Ù. ¾ÆÇÁ¸®Ä«¿Í ¾Æ½Ã¾ÆÀÇ ÀϺΠµî Ãâ»ýÀ²ÀÌ ³ôÀº ³ª¶ó¿Í Áö¿ª¿¡¼­´Â 5¼¼ ¹Ì¸¸ÀÇ ¾î¸°ÀÌ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, DPT ¹é½ÅÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. DPT´Â BÇü °£¿°À̳ª ¼Ò¾Æ¸¶ºñ¿Í °°Àº ´Ù¸¥ ¹é½Å°ú º´¿ëµÇ´Â °æ¿ì°¡ ¸¹¾Æ, Åõ¿©°¡ ¿ëÀÌÇϱ⠶§¹®¿¡ ½ÃÀå ħÅõÀ²ÀÌ Çâ»óÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹é½Å º¸°ü ¹× À¯ÅëÀÇ Áøº¸·Î ¿ø°ÝÁö¿¡¼­ÀÇ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ¸é¿ª·Â ÀúÇÏ·Î ÀÎÇÑ ¹éÀÏÇØÀÇ Á¤±âÀûÀÎ À¯ÇàÀº ºÎ½ºÅÍ Á¢Á¾°ú ³ôÀº Á¢Á¾·üÀÇ Çʿ伺À» °­Á¶ÇÕ´Ï´Ù. µðÇÁÅ׸®¾Æ³ª ¹éÀÏÇØ¿Í °°Àº ÁúȯÀÇ ¹Ú¸ê ¹× Á¦¾Ð Ȱµ¿¿¡¼­´Â DPT ¹é½ÅÀÌ ¿ì¼±µÇ°í ÀÖ½À´Ï´Ù. ¸ðü ¹× ½Å»ý¾Æ ÆÄ»ódz(MNT) ¹èÁ¦ ÇÁ·Î±×·¥°ú °°Àº ³ë·ÂÀº ÀϰüµÈ ¹é½Å ¼·Ã븦 Áö¿øÇÕ´Ï´Ù.

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 8.30%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Çüº°·Î ÁÖ·Î WHOÀÇ ±ÇÀå»çÇ׿¡ µû¶ó DTaP ¹é½Å ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

¿¬·É´ëº°·Î ¼Ò¾ÆºÎ¹®Àº 2023³â¿¡ ÁÖ¿ä ¿¬·É´ë ºÎ¹®ÀÌ µÇ¾ú½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø ºÎ¹®Àº 2023³â ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ ºÎ¹®À̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾Æ ±¹°¡ÀÇ Àα¸ Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°èÀÇ µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀåÀº À¯Çüº°, ¿¬·É´ëº°, ÃÖÁ¾ »ç¿ëÀÚº° ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

½ÃÀåÀº À¯Çüº°·Î 3°¡Áö·Î ºÐ·ùµË´Ï´Ù. : DTaP ¹é½Å, TD ¹é½Å, TDaP ¹é½ÅÀÔ´Ï´Ù. DTaP ¹é½Å ºÐ¾ß´Â ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù. °¨¿°ÀÇ È®»êÀ» ¿¹¹æÇÏ´Â ¿ä±¸ Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÕ´Ï´Ù.

½ÃÀåÀº ¿¬·É´ë¿¡ µû¶ó ¼ºÀΰú ¼Ò¾ÆÀÇ µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ¼Ò¾Æ ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼Ò¾Æ ±×·ìÀÇ ÀÎ½Ä Áõ°¡´Â ÁÖ·Î ºÎ¹® ¼ºÀåÀ» º¸¿ÏÇÕ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø, Ŭ¸®´Ð, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. WHO¿Í À¯´Ï¼¼ÇÁÀÇ ¸ñÇ¥ÀÎ ÀÓ»êºÎ ÆÄ»ódz ¹Ú¸ê, ¼Ò¾Æ¸¶ºñ µî ¹é½ÅÁ¢Á¾ ÇÁ·Î±×·¥ Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : Áö¿ªº° ºÐ¼®

Áö¿ªº°·Î´Â ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ª¿¡ ÆÛÁ® ÀÖ½À´Ï´Ù. ºÏ¹Ì¿¡¼­´Â °øÁߺ¸°ÇÀÇ ¾ö°ÝÇÑ Àǹ«È­·Î ¹é½ÅÁ¢Á¾·üÀÌ ³ô½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó°¡ È®¸³µÇ¾î Àֱ⠶§¹®¿¡ ¹é½Å¿¡ÀÇ ¾×¼¼½ºµµ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Àεµ, Áß±¹, µ¿³²¾Æ½Ã¾Æ µî ±¹°¡¿¡¼­ Ãâ»ý·üÀÌ ³ô°í À¯¾Æ Àα¸°¡ ¸¹±â ¶§¹®¿¡ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. GAVI¿Í WHO¿Í °°Àº ¼¼°èÀû Á¶Á÷¿¡ ÀÇÇÑ Àú¼Òµæ Áö¿ªÀÇ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥ Áö¿øÇÕ´Ï´Ù. Àεµ¿Í Áß±¹Àº ¹é½ÅÀÇ ¼Òºñ±¹ÀÌµç »ý»ê±¹À̵ç ÁÖ¿ä ½ÃÀåÀÔ´Ï´Ù.

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : °æÀï ±¸µµ

µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀåÀº ÁÖ¿ä Á¦¾à ±â¾÷ °£ÀÇ Ä¡¿­ÇÑ °æÀï, Áö¼ÓÀûÀÎ Çõ½Å, Àü·«Àû ÆÄÆ®³Ê½ÊÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. ½ÃÀåÀº BÇü °£¿°°ú Hib¿Í °°Àº Áúº´¿¡ ´ëÇÑ Ãß°¡ Ç׿øÀ» Æ÷ÇÔÇÑ 5°¡ ¹× 6°¡ Á¦Á¦¿Í °°Àº °í±Þ È¥ÇÕ ¹é½ÅÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ Á¾ÇÕÀûÀÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ÇÊ¿äÇÑ ÁÖ»ç Ƚ¼ö¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. Johnson & Johnson, GSK, Serum Institute, Bionet-Asia, and Meiji Holdings´Â DPT ¹é½Å ºÐ¾ßÀÇ À¯¸íÇÑ ±â¾÷ÀÔ´Ï´Ù.

2023³â¿¡´Â Sanofi Pastour°¡ ¹Ì±¹ ½ÃÀå¿¡¼­ ÇÑ ¹ø¿¡ 6ȸ Á¢Á¾ÇÒ ¼ö ÀÖ´Â Çí»ç½Ã¸¶¸¦ Ãâ½ÃÇß½À´Ï´Ù.

2022³â, Merck&Co.´Â ¼­¸ð½º¿Í Á¦ÈÞÇÏ¿© ¹é½ÅÀÇ º¸°ü ¹× À¯Åë ±â¼úÀ» °­È­Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå »óȲ

Á¦7Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : À¯Çüº°

Á¦8Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : ¿¬·ÉÃþº°

Á¦9Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ ¹× ÆÄ»ódz(DPT) ¹é½Å ¾÷°è

12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ ºÐ¼®

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market End User was valued at USD 5,620.32 Million in 2023, expanding at a CAGR of 8.30% from 2024 to 2032.

The Diphtheria, Pertussis, and Tetanus (DPT) vaccine is a combination vaccine that provides protection against serious bacterial infections. These vaccines reduce the risk of infection and serious complications, especially in young children.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Market Dynamics

Increasing prevalence of DPT-related diseases among infant & children and rising awareness spread by government programs is expected to propel market demand

Increased efforts by governments and organizations to educate populations about the importance of vaccination is promoting market growth. Programs like WHO's Expanded Program on Immunization (EPI) and GAVI, the Vaccine Alliance, emphasize the need for widespread immunization against DPT-related diseases. Improved understanding of the risks of diphtheria, pertussis, and tetanus, particularly in children, drives demand. Also, the inclusion of the DPT vaccine in national immunization schedules boosts market demand. Many governments provide vaccines at little or no cost, making them accessible to underserved populations.

Infants and young children are particularly susceptible to DPT-related diseases. In the countries or regions with high birth rates, such as Africa and parts of Asia, the growing number of children under five drives the need for DPT vaccines. DPT is often combined with other vaccines like hepatitis B, polio for ease of administration, improving market penetration. Additionally, advancements in vaccine storage and distribution enhance accessibility in remote areas. Periodic pertussis outbreaks due to waning immunity have underscored the need for booster doses and high vaccination rates. Eradication and control efforts for diseases like diphtheria and pertussis prioritize DPT vaccines. Initiatives like maternal and neonatal tetanus (MNT) elimination programs support consistent vaccine uptake.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.30% over the forecast period (2024-2032)

Based on Type segmentation, the DTaP vaccines segment was predicted to show maximum market share in the year 2023, mainly owing to WHO's recommendation.

Based on Age Group segmentation, the pediatrics segment was the leading Age Group segment in 2023, due to mandatory DTP vaccines made by WHO norms.

Based on End User segmentation, the hospitals segment was the leading End User segment in 2023, mainly due to rising awareness among people about vaccination & programs by hospitals.

On the basis of region, Asia Pacific was the leading revenue generator in 2023, due to the rise in the population across Asian countries.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Segmentation Analysis:

Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market is segmented on the basis of Type, Age Group, End User, and Region.

The market is divided into three categories based on the Type: DTaP vaccines, TD vaccines, and TDaP vaccines. The DTaP vaccines segment dominates the market. The growing need to prevent infectious disease prevalence is boosting segment growth.

The market is divided into two categories based on Age Group: adults and pediatrics. The pediatrics segment dominates the market. The increasing awareness among pediatrics groups about pre-vaccination programs is primarily supplementing segment growth.

The market is divided into three categories based on End User: hospitals, clinics, and others. The hospital segment is anticipated to grow at the fastest rate over the forecast period. The growing number of vaccination programs with WHO & UNICEF goals with maternal tetanus elimination, polios are expected to foster market demand.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In North America, there is high vaccination coverage due to stringent public health mandates. Established healthcare infrastructure ensures widespread vaccine access. In Asia Pacific, rapidly growing due to high birth rates and large infant populations in countries like India, China, and Southeast Asia. Support from global organizations such as GAVI, WHO for immunization programs in low-income areas. India and China are major markets, both as vaccine consumers and producers.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Competitive Landscape:

The Diphtheria, Pertussis, and Tetanus (DPT) vaccine market is characterized by intense competition among major pharmaceutical companies, continuous innovations, and strategic partnerships. The market is moving towards advanced combination vaccines like pentavalent and hexavalent formulations, which include additional antigens for diseases like hepatitis B and Hib. These innovations reduce the number of injections required for comprehensive immunization programs. Johnson & Johnson, GSK, Serum Institute, Bionet-Asia, and Meiji Holdings are some of the prominent players in the DPT vaccine space.

In 2023, Sanofi Pasteur launched Hexacima a six in a one immunization Vaccine in the U.S. market.

In 2022, Merck & Co. collaborated with Thermos to enhance vaccine storage and distribution technologies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT) VACCINE MARKET KEY PLAYERS

GLOBAL DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT) VACCINE MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT) VACCINE MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019-2032

GLOBAL DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT) VACCINE MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT) VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Overview

2. Executive Summary

3. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Key Market Trends

4. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Industry Study

5. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market: COVID-19 Impact Analysis

6. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Landscape

7. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market - By Type

8. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market - By Age Group

9. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market - By End User

10. Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- By Geography

11. Key Vendor Analysis- Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â